This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
FMSPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
Is Generics Still a Quiet Profit Engine for Cardinal Health?
by Indrajit Bandyopadhyay
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
CAHNegative Net Change MCKPositive Net Change CORPositive Net Change
medical medical-devices
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
by Indrajit Bandyopadhyay
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
HIMSPositive Net Change NVONegative Net Change LLYNegative Net Change
medical medical-devices
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
by Zacks Equity Research
HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
HIMSPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
by Harshit Gupta
Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
SOLVNegative Net Change MMMPositive Net Change MDTNegative Net Change
medical medical-devices
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
by Harshit Gupta
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
PACBPositive Net Change TMOPositive Net Change ILMNPositive Net Change
medical medical-devices
HQY Up 15.7% in 3 Months as HSA Growth Builds: Can the Rally Continue?
by Harshit Gupta
HealthEquity's 15.7% three-month rally is backed by rising HSA scale, stronger margins and higher guidance, though key risks remain.
HQYPositive Net Change UNHNegative Net Change WEXPositive Net Change
medical medical-devices
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
by Zacks Equity Research
ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
ENOVPositive Net Change COONegative Net Change WSTPositive Net Change GMEDPositive Net Change
medical medical-devices
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
by Zacks Equity Research
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
MMSINegative Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
GEHC Wins CE Mark for Photonova Spectra, Expands International Reach
by Zacks Equity Research
GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.
GEHCNegative Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices